Hal Barron, GSK via YouTube
What does $29B buy you in Big Pharma? In GlaxoSmithKline’s case, a whole lot of uncomfortable questions about the pipeline
Talk about your bad timing.
A little over a week ago, GSK R&D chief Hal Barron marked his third anniversary at the research helm by …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
